Roche (OTCMKTS:RHHBY) Shares Pass Below 50 Day Moving Average – Time to Sell?

Roche Holding AG (OTCMKTS:RHHBY) shares passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $36.86 and traded as low as $34.71. Roche shares last traded at $35.00, with a volume of 970,153 shares trading hands.

Analysts Set New Price Targets

Several analysts have recently weighed in on RHHBY shares. Bank of America upgraded shares of Roche from a “neutral” rating to a “buy” rating in a research report on Friday, September 13th. Deutsche Bank Aktiengesellschaft lowered Roche from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Three analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the stock. According to MarketBeat, Roche currently has an average rating of “Hold”.

Roche Stock Up 0.2 %

The stock’s 50 day moving average price is $36.78 and its 200-day moving average price is $37.90.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Brooklyn Investment Group bought a new position in Roche during the 3rd quarter worth approximately $40,000. AlphaMark Advisors LLC bought a new position in shares of Roche in the third quarter worth approximately $149,000. Archer Investment Corp increased its stake in shares of Roche by 10.6% in the second quarter. Archer Investment Corp now owns 6,810 shares of the company’s stock worth $236,000 after buying an additional 652 shares during the period. IHT Wealth Management LLC bought a new stake in Roche during the 3rd quarter valued at $236,000. Finally, Verity Asset Management Inc. purchased a new stake in Roche during the 3rd quarter valued at $253,000.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.